An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 6-18

  Pandya, Hetal ^a   Gibo, Denise M ^a   Garg, Shivank ^a   Kridel, Steven ^a   Debinski, Waldemar ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain tumor barrier; GBM; Interleukin 13 receptor 2; Peptide phagesdisplay library; Peptides; Xenografts

Indexed keywords

HEPTAPEPTIDE; INTERLEUKIN 13 RECEPTOR ALPHA2; LIGAND; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOPANNING; BLOOD BRAIN BARRIER; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN ISOLATION; TUMOR XENOGRAFT;

ANIMALS; BINDING, COMPETITIVE; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, NUDE; PEPTIDE LIBRARY; PEPTIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856258774     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor141     Document Type: Article

References (33)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta. Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
2. Stupp R, Dietrich PY, Ostermann SK, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002;20(5):1375-1382. (Pubitemid 34177445)
3. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer. Res. 1999;5(5):985-990. (Pubitemid 29233211)
4. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol. Cancer. Res. 2005;3(4):237-249. (Pubitemid 40525334)
5. Wykosky J, Gibo DM, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of highgrade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer. Res. 2008;14(1):199-208. (Pubitemid 351377996)
6. DebinskiW, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 1996;271(37):22428-22433. (Pubitemid 26304677)
7. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin. Cancer. Res. 2003;9(17):6381-6388. (Pubitemid 38031823)
8. Kornmann M, Kleeff J, Debinski W, Korc M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer. Res. 1999;19(1A):125-131. (Pubitemid 29168228)
9. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: A potential biomarker and molecular target for ovarian cancer therapy. Cancer. 2006;107(6):1407-1418. (Pubitemid 44452792)
10. Gonzalez-Moreno O, Calvo A, Joshi BH, et al. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int. J. Cancer. 2005;114(6):870-878.
11. Hershey GK. IL-13 receptors and signaling pathways: An evolving web. J. Allergy. Clin. Immunol. 2003;111(4):677-690. (Pubitemid 36470232)
12. Bernard J, Treton D, Vermot-Desroches C, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab. Invest. 2001;81(9):1223-1231. (Pubitemid 32911971)
13. Fichtner-Feigl S, StroberW, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 2006;12(1):99-106. (Pubitemid 43050083)
14. Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat. Biotechnol. 1998;16(5):449-453. (Pubitemid 28211197)
15. Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia. 2004;6(1):15-22. (Pubitemid 38391945)
16. Thompson JP, Debinski W. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors. J. Biol. Chem. 1999;274(42):29944- 29950.
17. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer. Res. 1995;1(11):1253-1258.
18. Mintz A, Gibo DM, Madhankumar AB, DebinskiW. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J. Neurooncol. 2003;64(1-2):117-123. (Pubitemid 36992466)
19. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J. Neurosurg. 2010;113(2):301-309.
20. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm. 2007;4(5):631-651. (Pubitemid 350004263)
21. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-380. (Pubitemid 28063372)
22. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrinreleasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J. Med. Chem. 2009;52(2):425-432.
23. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J. Nucl. Med. 2008;49(11):1735-1738.
24. Madhankumar AB, Mintz A, DebinskiW. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J. Biol. Chem. 2002;277(45): 43194-43205. (Pubitemid 35285705)
25. Rasmussen UB, Schreiber V, Schultz H, Mischler F, Schughart K. Tumor cell-targeting by phages-displayed peptides. Cancer. Gene. Ther. 2002;9(7):606-612.
26. Wang J, Liu Y, Teesalu T, et al. Selection of phages-displayed peptides on live adherent cells in microfluidic channels. PNAS. 2011;108(17):6909-6914.
27. Staquicini FI, Ozawa MG, Moya CA, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 2011;121(1):161-173.
28. Han Z, Fu A, Wang H, et al. Noninvasive assessment of cancer response to therapy. Nat. Med. 2008;14(3):343-349. (Pubitemid 351347907)
29. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: An in vitro evaluation using human cell lines. J. Neurooncol. 2008;86(2):165-172. (Pubitemid 350263413)
30. Pandya H, Gibo DM, Debinski W. Molecular targeting of intracellular compartments specifically in cancer cells. Genes & Cancer. 2010;1(5):421-433.
31. Madhankumar AB, Slagle-Webb B, Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer. Ther. 2009;8(3): 648-654.
32. Mueller S, Polley MY, Lee B, et al. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J. Neurooncol. 2011;101(2):267-277.
33. Stummer W, Reulen HJ, Meinel T, et al. ALA-Glioma Study Group, Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery. 2008;62(3): 564-576.